Patents by Inventor Lihui Weng
Lihui Weng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230095373Abstract: The present disclosure is generally directed to an embolic material which, in some embodiments, may be in the form of a microsphere or a plurality of microspheres. The embolic material generally comprises carboxymethyl chitosan (CCN) crosslinked with carboxymethyl cellulose (CMC). In some embodiments, the embolic material may further comprise a therapeutic agent, such as doxorubicin.Type: ApplicationFiled: September 12, 2022Publication date: March 30, 2023Inventors: Jafar Golzarian, Lihui Weng
-
Patent number: 11439725Abstract: The present disclosure is generally directed to an embolic material which, in some embodiments, may be in the form of a microsphere or a plurality of microspheres. The embolic material generally comprises carboxymethyl chitosan (CCN) crosslinked with carboxymethyl cellulose (CMC). In some embodiments, the embolic material may further comprise a therapeutic agent, such as doxorubicin.Type: GrantFiled: November 30, 2018Date of Patent: September 13, 2022Assignee: Regents of the University of MinnesotaInventors: Jafar Golzarian, Lihui Weng
-
Publication number: 20190091368Abstract: The present disclosure is generally directed to an embolic material which, in some embodiments, may be in the form of a microsphere or a plurality of microspheres. The embolic material generally comprises carboxymethyl chitosan (CCN) crosslinked with carboxymethyl cellulose (CMC). In some embodiments, the embolic material may further comprise a therapeutic agent, such as doxorubicin.Type: ApplicationFiled: November 30, 2018Publication date: March 28, 2019Inventors: Jafar Golzarian, Lihui Weng
-
Patent number: 10182979Abstract: The present disclosure describes a plurality of microspheres that include carboxymethyl chitosan (CCN) crosslinked with carboxymethyl cellulose (CMC). The microspheres are biocompatible, bioresorbable, and biodegradable. The microspheres may be used in personal care products, such as, for example, toothpaste, topical pain relief products, topical antibiotic products, skincare products such as anti-wrinkle products, eczema products, skin scrubs, acne cleansers, exfoliators, body washes, soaps, pre-shave creams, or the like.Type: GrantFiled: March 22, 2017Date of Patent: January 22, 2019Assignees: Regents of the University of Minnesota, EmboMedics, Inc.Inventors: Lihui Weng, Jafar Golzarian, Omid Souresrafil
-
Patent number: 10179187Abstract: The present disclosure is generally directed to an embolic material which, in some embodiments, may be in the form of a microsphere or a plurality of microspheres. The embolic material generally comprises carboxymethyl chitosan (CCN) crosslinked with carboxymethyl cellulose (CMC). In some embodiments, the embolic material may further comprise a therapeutic agent, such as doxorubicin.Type: GrantFiled: December 5, 2013Date of Patent: January 15, 2019Assignee: Regents of the University of MinnesotaInventors: Jafar Golzarian, Lihui Weng
-
Publication number: 20180078661Abstract: The present disclosure is generally directed to an embolic material which, in some examples, may be in the form of a microsphere or a plurality of microspheres. The embolic material may include carboxymethyl chitosan (CCN) crosslinked with partially oxidized carboxymethyl cellulose (OCMC) and an imaging agent such as at least one of an ethiodized oil, a radiopaque metal, or super paramagnetic iron oxide nanoparticles integrally contained within the microsphere.Type: ApplicationFiled: September 19, 2017Publication date: March 22, 2018Inventors: Lihui Weng, Jafar Golzarian
-
Publication number: 20170273888Abstract: The present disclosure describes a plurality of microspheres that include carboxymethyl chitosan (CCN) crosslinked with carboxymethyl cellulose (CMC). The microspheres are biocompatible, bioresorbable, and biodegradable. The microspheres may be used in personal care products, such as, for example, toothpaste, topical pain relief products, topical antibiotic products, skincare products such as anti-wrinkle products, eczema products, skin scrubs, acne cleansers, exfoliators, body washes, soaps, pre-shave creams, or the like.Type: ApplicationFiled: March 22, 2017Publication date: September 28, 2017Inventors: Lihui Weng, Jafar Golzarian, Omid Souresrafil
-
Publication number: 20160243244Abstract: A system for providing a drug-eluting resorbable hydrogel for treating chronic pain, the system including carboxymethyl chitosan and oxidized carboxymethyl cellulose solutions, which together with one or more bioactive agents, can be mixed and delivered at the time of use in order to gel in situ within a joint space. Once delivered, the hydrogel can provide bioactive agents such as NSAIDs directly to the areas commonly associated with chronic pain, including to the spine, knee, shoulder, and elbow. The hydrogel is substantially non-inflammatory, and substantially biodegradable over time, to provide prolonged drug release.Type: ApplicationFiled: February 19, 2016Publication date: August 25, 2016Inventors: Jafar Golzarian, Lihui Weng, Omid Souresrafil
-
Patent number: 8936795Abstract: A liquid embolic material may include a mixture of a first solution comprising between about 1.2% and about 2.5% weight per volume (w/v) carboxymethyl chitosan (CCN) in a first solvent and a second solution comprising between about 1.2% and about 2.5% w/v oxidized carboxymethyl cellulose (OCMC) in a second solvent. The liquid embolic material may be used to embolize a targeted embolization location by mixing the first solution and the second solution to form a liquid embolic material (or hydrogel precursor material), introducing the hydrogel precursor material to a targeted embolization location within a body of a patient, and allowing the CCN and the OCMC to react to form the hydrogel material and embolize the targeted embolization location.Type: GrantFiled: December 19, 2012Date of Patent: January 20, 2015Assignee: Regents of the University of MinnesotaInventors: Jafar Golzarian, Lihui Weng
-
Publication number: 20140171907Abstract: A liquid embolic material may include a mixture of a first solution comprising between about 1.2% and about 2.5% weight per volume (w/v) carboxymethyl chitosan (CCN) in a first solvent and a second solution comprising between about 1.2% and about 2.5% w/v oxidized carboxymethyl cellulose (OCMC) in a second solvent. The liquid embolic material may be used to embolize a targeted embolization location by mixing the first solution and the second solution to form a liquid embolic material (or hydrogel precursor material), introducing the hydrogel precursor material to a targeted embolization location within a body of a patient, and allowing the CCN and the OCMC to react to form the hydrogel material and embolize the targeted embolization location.Type: ApplicationFiled: December 19, 2012Publication date: June 19, 2014Applicant: REGENTS OF THE UNIVERSITY OF MINNESOTAInventors: Jafar Golzarian, Lihui Weng
-
Publication number: 20140099374Abstract: The present disclosure is generally directed to an embolic material which, in some embodiments, may be in the form of a microsphere or a plurality of microspheres. The embolic material generally comprises carboxymethyl chitosan (CCN) crosslinked with carboxymethyl cellulose (CMC). In some embodiments, the embolic material may further comprise a therapeutic agent, such as doxorubicin.Type: ApplicationFiled: December 5, 2013Publication date: April 10, 2014Applicant: REGENTS OF THE UNIVERSITY OF MINNESOTAInventors: Jafar Golzarian, Lihui Weng
-
Patent number: 8617132Abstract: The present disclosure is generally directed to an embolic material which, in some embodiments, may be in the form of a microsphere or a plurality of microspheres. The embolic material generally comprises carboxymethyl chitosan (CCN) crosslinked with carboxymethyl cellulose (CMC). In some embodiments, the embolic material may further comprise a therapeutic agent, such as doxorubicin.Type: GrantFiled: October 6, 2010Date of Patent: December 31, 2013Assignee: Regents of the University of MinnesotaInventors: Jafar Golzarian, Lihui Weng
-
Publication number: 20110082427Abstract: The present disclosure is generally directed to an embolic material which, in some embodiments, may be in the form of a microsphere or a plurality of microspheres. The embolic material generally comprises carboxymethyl chitosan (CCN) crosslinked with carboxymethyl cellulose (CMC). In some embodiments, the embolic material may further comprise a therapeutic agent, such as doxorubicin.Type: ApplicationFiled: October 6, 2010Publication date: April 7, 2011Applicant: Regents of the University of MinnesotaInventors: Jafar Golzarian, Lihui Weng
-
Publication number: 20100233267Abstract: The present invention features a composite hydrogel for use as soft tissue substitutes and transitional three-dimensional support structures.Type: ApplicationFiled: February 1, 2008Publication date: September 16, 2010Applicant: The Research Foundation of State University of New YorkInventors: Weiliam Chen, Lihui Weng, Hui Pan
-
Patent number: 7763268Abstract: The present invention features dual network hydrogels that possess the structural, mechanical, and biological properties required of load bearing three-dimensional support structures.Type: GrantFiled: January 16, 2009Date of Patent: July 27, 2010Assignee: The Research Foundation of State University of New YorkInventors: Weiliam Chen, Lihui Weng
-
Publication number: 20100029789Abstract: The present invention features dual network hydrogels that possess the structural, mechanical, and biological properties required of load bearing three-dimensional support structures.Type: ApplicationFiled: January 16, 2009Publication date: February 4, 2010Inventors: Weiliam Chen, Lihui Weng